Chondrial Therapeutics has licensed the investigational compound CTI-1601 for treating  Friedreich’s ataxia (FA) from Indiana University Research and Technology…
Articles by Margarida Azevedo, MSc
American researchers have come up with a new, non-invasive way to measure mitochondrial function in human skeletal muscle, a development that…
The Friedreich’s Ataxia Center of Excellence at The Children’s Hospital of Philadelphia is presenting a one-day annual symposium on…
Early results from Retrotope‘s Phase 1/2 clinical trial assessing RT001 as a potential treatment for Friedreich’s ataxia (FA) show that it has met…
KRAM Wellness’ flagship product, Flexfit, is a three-in-one injury prevention product that provides a controlled stretch using an adjustable, non-elastic design.
The nonprofit Global Genes, an organization for patients and families fighting rare and genetic diseases, is awarding more than $100,000 in travel…
Pfizer recently acquired the biotech Bamboo Therapeutics which develops therapies for potential treatment of patients with neuromuscular and central nervous system (CNS) rare diseases…
The U.S. Food and Drug Administration (FDA) has designated AGIL-FA, a gene therapy from Agilis Biotherapeutics intended as a potential treatment of Friedreich’s…
Whether or not to participate in a clinical trial is a hard decision to make — but when it comes to…
A new form of sun protection that works by chelating, or binding, excess iron within mitochondria may not only protect against UVA rays that…